- Home
- EYPT
as 07-26-2024 4:00pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 488.6M | IPO Year: | 2005 |
| Target Price: | $32.80 | AVG Volume (30 days): | 901.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.67 - $30.99 | Next Earning Date: | 08-05-2024 |
| Revenue: | $50,019,000 | Revenue Growth: | 25.70% |
| Revenue Growth (this year): | -12.93% | Revenue Growth (next year): | -66.06% |
Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GUYER DAVID R | EYPT | Director | Jul 12 '24 | Sell | $10.06 | 11,625 | $116,995.16 | 1,850 | SEC Form 4 |
| GUYER DAVID R | EYPT | Director | Jun 3 '24 | Sell | $10.30 | 11,625 | $119,704.95 | 3,700 | SEC Form 4 |
| GUYER DAVID R | EYPT | Director | May 14 '24 | Sell | $12.65 | 11,625 | $147,044.63 | 5,550 | SEC Form 4 |
| Cormorant Asset Management, LP | EYPT | 10% Owner | May 6 '24 | Buy | $11.70 | 642,847 | $7,521,309.90 | 8,117,847 | SEC Form 4 |
| Cormorant Asset Management, LP | EYPT | 10% Owner | May 6 '24 | Buy | $12.36 | 207,153 | $2,560,411.08 | 8,325,000 | SEC Form 4 |
| Cormorant Asset Management, LP | EYPT | 10% Owner | Apr 18 '24 | Buy | $17.62 | 395,244 | $6,964,199.28 | 7,288,479 | SEC Form 4 |
| Cormorant Asset Management, LP | EYPT | 10% Owner | Apr 18 '24 | Buy | $18.90 | 186,521 | $3,525,246.90 | 7,475,000 | SEC Form 4 |
| Jones David Scott | EYPT | SVP & Chief Commercial Officer | Feb 2 '24 | Sell | $28.49 | 209 | $5,954.41 | 37,962 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 26 '24 | Sell | $25.41 | 51 | $1,295.74 | 85,779 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 26 '24 | Sell | $25.41 | 15,609 | $396,571.62 | 70,170 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 26 '24 | Sell | $25.77 | 33,665 | $867,671.61 | 36,505 | SEC Form 4 |
| Jones David Scott | EYPT | SVP & Chief Commercial Officer | Jan 26 '24 | Sell | $25.45 | 16,413 | $417,653.40 | 47,566 | SEC Form 4 |
| Jones David Scott | EYPT | SVP & Chief Commercial Officer | Jan 26 '24 | Sell | $25.27 | 9,604 | $242,717.09 | 37,962 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 25 '24 | Sell | $25.00 | 300 | $7,500.00 | 36,805 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 25 '24 | Sell | $25.00 | 300 | $7,500.00 | 36,505 | SEC Form 4 |
| Jones David Scott | EYPT | SVP & Chief Commercial Officer | Jan 24 '24 | Sell | $25.01 | 5,700 | $142,553.58 | 43,562 | SEC Form 4 |
| Jones David Scott | EYPT | SVP & Chief Commercial Officer | Jan 24 '24 | Sell | $25.01 | 5,600 | $140,067.76 | 37,962 | SEC Form 4 |
| Jones David Scott | EYPT | SVP & Chief Commercial Officer | Jan 24 '24 | Sell | $25.00 | 300 | $7,500.00 | 38,262 | SEC Form 4 |
| Jones David Scott | EYPT | SVP & Chief Commercial Officer | Jan 24 '24 | Sell | $25.00 | 300 | $7,500.00 | 37,962 | SEC Form 4 |
| Lurker Nancy | EYPT | Executive Vice Chair | Jan 23 '24 | Sell | $24.97 | 5,044 | $125,949.69 | 165,397 | SEC Form 4 |
| Lurker Nancy | EYPT | Executive Vice Chair | Jan 23 '24 | Sell | $24.98 | 29,956 | $748,249.95 | 135,441 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 23 '24 | Sell | $25.00 | 2,039 | $50,975.00 | 39,601 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 23 '24 | Sell | $25.00 | 3,096 | $77,400.00 | 36,505 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 23 '24 | Sell | $25.01 | 5,600 | $140,052.08 | 42,156 | SEC Form 4 |
| Paggiarino Dario A. | EYPT | Chief Medical Officer | Jan 23 '24 | Sell | $25.02 | 5,651 | $141,363.16 | 36,505 | SEC Form 4 |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
12 days ago
Milestone Pharmaceuticals Refreshes Board of Directors
GlobeNewswire
a month ago
EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
GlobeNewswire
a month ago
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
Zacks
a month ago
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
GlobeNewswire
a month ago
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
GlobeNewswire
a month ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.